20 citations
,
December 2021 in “Journal of the American Academy of Dermatology” Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.
March 2003 in “International Journal of Antimicrobial Agents” Blocking 5α-reductase can reduce sleep deprivation-related behavioral issues in rats.
March 2026 in “American Journal of Clinical Dermatology” Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.
June 2023 in “Frontiers in Cardiovascular Medicine” Using existing drugs for new purposes could be a cost-effective way to treat chest pain and non-clogged heart arteries, with some drugs for lung blood pressure showing promise but needing more testing.
July 2025 in “Journal of Investigative Dermatology” Low-dose oral minoxidil is safe for the heart in the short term for hair loss patients.
19 citations
,
June 2011 in “British Journal of Dermatology” Severe digestive issues in DRESS need early endoscopy for better treatment.
August 2024 in “Journal of Personalized Medicine” Tamsulosin increases the risk of floppy iris during eye surgery.
2 citations
,
July 2022 in “Journal of the American Academy of Dermatology” The safety and tolerability of low-dose oral minoxidil for treating hair loss in adolescents is not clearly determined.
August 2025 in “Tropical Journal of Natural Product Research” LEON gel significantly boosts hair growth without irritation.
4 citations
,
March 2025 in “The Journal of Dermatology” Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.
6 citations
,
January 2021 in “Journal of The American Academy of Dermatology” Low-dose oral minoxidil can be effective for hair loss but should be avoided in people with certain heart conditions and severe liver problems.
13 citations
,
March 2014 in “Journal of the American Medical Directors Association” Trichotillomania was successfully treated with risperidone and naltrexone.
August 2025 in “BMC Pharmacology and Toxicology” The LTF gene may help predict and manage nonspecific orbital inflammation.
June 2025 in “British Journal of Dermatology” Low-dose oral minoxidil is increasingly used by dermatologists in the UK and Ireland to treat various hair loss conditions.
A medicine company has recalled a drug because it contained an unlisted blood pressure medication.
2 citations
,
November 2025 in “Journal of the American Academy of Dermatology” Deuruxolitinib effectively regrows hair in adults with alopecia areata and is well tolerated.
17 citations
,
October 2013 in “Der Hautarzt”
Lupus severely affects daily life, work, and mental health, with many experiencing frequent flares and medication side-effects.
2 citations
,
May 2013 in “The primary care companion for CNS disorders” A teenage girl's excessive hair growth was caused by a medication for mania, but improved after stopping the medication.
14 citations
,
March 2022 in “Plant Cell & Environment” The protein AtRXR3 limits root hair growth in Arabidopsis, affecting phosphorus uptake.
October 2025 in “Dermatology and Therapy” Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
25 citations
,
September 2018 in “Scientific Reports” Morroniside may help hair grow and stay in its growth phase by affecting certain cell signals.
12 citations
,
October 1978 in “PubMed” Ro 10-9359 is an effective treatment for severe psoriasis but can cause side effects.
1 citations
,
December 2025 in “Iraqi Journal of Pharmaceutical Sciences ( P-ISSN 1683 - 3597 E-ISSN 2521 - 3512)” Spanlastics effectively deliver Rizatriptan Benzoate with high efficiency and controlled release.
August 2011 in “Reactions Weekly” A man with lung cancer had skin and eye side effects from erlotinib but continued treatment with symptom improvement.
1 citations
,
September 2023 in “Dermatology online journal” Low dose oral minoxidil can help with hair growth but may cause serious heart problems, so doctors need to be careful.
January 1999 in “Universitas Philosophica” Cornifin-alpha/SPRR1 is increased in certain skin conditions and by specific treatments.